Lidocaine represses proliferation and cisplatin resistance in cutaneous squamous cell carcinoma via miR-30c/SIRT1 regulation

References

• Dreyfuss I, Kamath P, Frech F, et al. Squamous cell carcinoma: 2021 updated review of treatment. Dermatol Ther. 2022;1:e15308.
   Google Scholar
• Bi X, Jiang Z, Luan Z, et al. Crocin exerts anti-proliferative and apoptotic effects on cutaneous squamous cell carcinoma via miR-320a/ATG2B. Bioengineered. 2021;12(1):4569–4580.
   PubMed Web of Science ®Google Scholar
• Betlloch-Mas I, Soriano-García T, Boira I, et al. Cutaneous metastases of solid tumors: demographic, clinical, and survival characteristics. Cureus. 2021;13(11):e19970.
   PubMed Web of Science ®Google Scholar
• Corchado-Cobos R, García-Sancha N, González-Sarmiento R, et al. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):2956.
   PubMed Web of Science ®Google Scholar
• García-Sancha N, Corchado-Cobos R, Pérez-Losada J, et al. MicroRNA dysregulation in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(9):2181.
   PubMed Web of Science ®Google Scholar
• Santos P, Almeida F. Role of exosomal miRNAs and the tumor microenvironment in drug resistance. Cells. 2020;9(6):1450.
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–333.
   PubMed Web of Science ®Google Scholar
• Huang YQ, Ling XH, Yuan RQ, et al. miR30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein. Mol Med Rep. 2017;16:2431–2438.
   PubMed Web of Science ®Google Scholar
• McCann JV, Xiao L, Kim DJ, et al. Endothelial miR-30c suppresses tumor growth via inhibition of TGF-beta-induced Serpine1. J Clin Invest. 2019;129(4):1654–1670.
   PubMed Web of Science ®Google Scholar
• Huang YQ, Ling XH, Yuan RQ, et al. miR-30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein. Mol Med Rep. 2017;16(3):2431–2438.
   PubMed Web of Science ®Google Scholar
• Davis AJ, Tsinkevich M, Rodencal J, et al. TAp63-Regulated miRNAs suppress cutaneous squamous cell carcinoma through inhibition of a network of cell-cycle genes. Cancer Res. 2020;80(12):2484–2497.
   PubMed Web of Science ®Google Scholar
• Giry-Laterriere M, Pinho AV, Eling N, et al. Emerging drug target in pancreatic cancer: placing Sirtuin 1 on the canvas. Curr Cancer Drug Targets. 2015;15(6):463–468.
   PubMed Web of Science ®Google Scholar
• Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019;20(13):3153.
   PubMed Web of Science ®Google Scholar
• Lu RH, Xiao ZQ, Zhou JD, et al. MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling. Cell Cycle. 2020;19(1):1–14.
   PubMed Web of Science ®Google Scholar
• Kobrine AI, Evans DE, LeGrys DC, et al. Effect of intravenous lidocaine on experimental spinal cord injury. J Neurosurg. 1984;60:595–601.
   PubMed Web of Science ®Google Scholar
• Cole DJ, Shapiro HM, Drummond JC, et al. Halothane, fentanyl/ nitrous oxide, and spinal lidocaine protect against spinal cord injury in the rat. Anesthesiology. 1989;70:967–972.
   PubMed Web of Science ®Google Scholar
• Chang YC, Hsu YC, Liu CL, et al. Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. PLoS One. 2014;9:e89563.
   PubMed Web of Science ®Google Scholar
• De Oliveira GJ, Fitzgerald P, Streicher LF, et al. Systemic lidocaine to improve postoperative quality of recovery after ambulatory laparoscopic surgery. Anesth Analg. 2012;115:262–267.
   PubMed Web of Science ®Google Scholar
• Soura E, Gagari E, Stratigos A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr Opin Oncol. 2019;31(5):461–468.
   PubMed Web of Science ®Google Scholar
• Mulvaney PM, Schmults CD. Molecular prediction of metastasis in cutaneous squamous cell carcinoma. Curr Opin Oncol. 2020;32(2):129–136.
   PubMed Web of Science ®Google Scholar
• Trodello C, Pepper JP, Wong M, et al. Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review. Dermatol Surg. 2017;43(1):40–49.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Goswami D, Adiseshaiah PP, et al. Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-Driven pancreatic cancers. Cancer Res. 2020;80(8):1630–1643.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kong Y, Yang W, et al. MicroRNA-218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin. Exp Ther Med. 2018;16:4796e4802.
   Web of Science ®Google Scholar
• Li X, Chen W, Jin Y, et al. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Biochem Pharmacol. 2019;161:98–112.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Zheng W, Liu J, et al. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 2020;67(1):93–101.
   PubMed Web of Science ®Google Scholar
• Zhao DW, Li MM, Han JP, et al. MiR-30c exerts tumor suppressive functions in colorectal carcinoma by directly targeting BCL9. Eur Rev Med Pharmacol Sci. 2019;23(8):3335–3343.
   PubMed Web of Science ®Google Scholar
• Liu S, Li X, Zhuang S. miR-30c impedes glioblastoma cell proliferation and migration by targeting SOX9. Oncol Res. 2019;27(2):165–171.
   PubMed Web of Science ®Google Scholar
• Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim Biophys Acta. 2010;1804(8):1684–1689.
   PubMed Web of Science ®Google Scholar
• Wang TW, Chern E, Hsu CW, et al. SIRT1-mediated expression of CD24 and epigenetic suppression of novel tumor suppressor miR-1185-1 increases colorectal cancer stemness. Cancer Res. 2020;80(23):5257–5269.
   PubMed Web of Science ®Google Scholar
• Jin X, Wei Y, Liu Y, et al. High expression of SIRT1 associates with the doxorubicin resistance of breast cancer through the activation of Akt. Anticancer Agents Med Chem. 2020;20(1):94–102.
   PubMed Web of Science ®Google Scholar
• Zu G, Ji A, Zhou T, et al. Clinicopathological significance of SIRT1 expression in colorectal cancer: a systematic review and meta analysis. Int J Surg. 2016;26:32–37.
   PubMed Web of Science ®Google Scholar
• Xu Y, Qin Q, Chen R, et al. SIRT1 promotes proliferation, migration, and invasion of breast cancer cell line MCF-7 by upregulating DNA polymerase delta1 (POLD1). Biochem Biophys Res Commun. 2018;502(3):351–357.
   PubMed Web of Science ®Google Scholar
• Jin J, Chu Z, Ma P, et al. SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells. Tumour Biol. 2017;39(3):1010428317691180.
   Google Scholar
• Ferguson C, Loryman B, Body R. Best evidence topic report. Topical anaesthetic versus lidocaine infiltration to allow closure of skin wounds in children. Emerg Med J. 2005;22(7):507–509.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Song Z, et al. Downregulation of microRNA-199a-5p alleviated lidocaine-induced sensory dysfunction and spinal cord myelin lesions in a rat model. Toxicol Lett. 2021;336:1–10.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie J, Liu W, et al. Lidocaine sensitizes the cytotoxicity of 5-fluorouacil in melanoma cells via upregulation of microRNA-493. Pharmazie. 2017;72(11):663–669.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ma N, Liu G, et al. Lidocaine inhibits hepatocellular carcinoma development by modulating circ_ITCH/miR-421/CPEB3 Axis. Dig Dis Sci. 2021;66(12):4384–4397.
   PubMed Web of Science ®Google Scholar
• Wen J, Li X, Ding Y, et al. Lidocaine inhibits glioma cell proliferation, migration and invasion by modulating the circEZH2/miR-181b-5p pathway. Neuroreport. 202132(1):52–60.
   Google Scholar
• Yang Q, Zhang Z, Xu H, et al. Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21. Mol Cell Biochem. 2019;456(1–2):63–72.
   PubMed Web of Science ®Google Scholar
• Zhang X, Gu G, Li X, et al. Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b. Cell Cycle. 2020;19(19):2530–2537.
   PubMed Web of Science ®Google Scholar